Jan
05
2026
News
Sep
29
2025
Tevard Biosciences Presents Data Showing Compelling Full-Length Protein Rescue with tRNA-based Treatment for Duchenne Muscular Dystrophy and Dilated Cardiomyopathy at the 2025 FEBS Special Meeting
Read more
Jun
10
2025
Tevard Biosciences Names Dr. Elisabeth Gardiner Chief Scientific Officer to Lead Next Phase of tRNA-Based Therapies
Read more
May
15
2025
Tevard Reports Data on Suppressor tRNA Therapy Restoring Full-Length Dystrophin in Duchenne Muscular Dystrophy Model
Read more
Apr
29
2025
Tevard to Present Data Demonstrating tRNA-based Therapy Rescued Full-Length Dystrophin and Motor Function in Duchenne Muscular Dystrophy Model
Read more
Aug
13
2024
Tevard Biosciences to Move Corporate Headquarters to Lilly Gateway Labs in Boston’s Seaport
Read more
Jun
24
2024
Industry Veteran and RNA Therapeutics Expert, John Maraganore, Joins Tevard Biosciences as Strategic Advisor and Board Observer
Read more
Aug
03
2022
Tevard Biosciences Appoints Zoya Ignatova to Its Scientific Advisory Board
Read more
Apr
26
2022
Tevard CEO Awarded Henri Termeer Fellowship
Read more
Mar
31
2022